None
Quote | Akero Therapeutics Inc. (NYSE:AKRO)
Last: | $ |
---|---|
Change Percent: | -7.69% |
Open: | $27.10 |
Close: | $24.97 |
High: | $27.10 |
Low: | $24.64 |
Volume: | 89,888 |
Last Trade Date Time: | 02/12/2020 04:42:16 pm |
News | Akero Therapeutics Inc. (NYSE:AKRO)
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...
Message Board Posts | Akero Therapeutics Inc. (NYSE:AKRO)
Subject | By | Source | When |
---|---|---|---|
Profit taking :__:) | subslover | investorshub | 01/04/2023 6:51:52 PM |
WOW | TheFinalCD | investorshub | 12/29/2022 10:46:20 PM |
$54 | subslover | investorshub | 12/29/2022 6:30:34 PM |
Hit $50.01 today! | subslover | investorshub | 12/28/2022 7:27:55 PM |
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY | subslover | investorshub | 12/23/2022 1:12:24 PM |
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
Akero Therapeutics Inc. Website:
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...
SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the ...